Xeris Biopharma Holdings Inc
NASDAQ:XERS

  • LAST PRICE
    2.1000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 2.1000
  • Day Range
    ---
  • 52 Week Range
    1.4600
    3.2600
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Pharmaceuticals - Diversified Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
XERS
Xeris Biopharma Holdings Inc
312.8M
-4.5x
---
TAK
Takeda Pharmaceutical Co Ltd
40.6B
45.4x
-8.01%
BVNRY
Bavarian Nordic A/S
1.8B
11.9x
---
ASRT
Assertio Holdings Inc
114.1M
-0.3x
---
SIGA
SIGA Technologies Inc
503.5M
6.7x
-28.78%
NAII
Natural Alternatives International Inc
39.8M
-11.1x
-18.19%
As of 2024-06-26

Company Information

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patients’ lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP). It also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. Its product candidate XP-8121, which is designed to be a once-weekly, small-volume, subcutaneous injection that bypasses the gastrointestinal tract and could avoid many therapeutic complications.

Contact Information

Headquarters
1375 West Fulton Street, Suite 1300CHICAGO, IL, United States 60607
Phone
302-658-7581
Fax
302-655-5049

Executives

Chairman of the Board, Chief Executive Officer
Paul Edick
President, Chief Operating Officer
John Shannon
Chief Financial Officer
Steven Pieper
Senior Vice President - Global Development and Medical Affairs
Kenneth Johnson
Chief Legal Officer, Corporate Secretary
Beth Hecht

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$311.3M
Revenue (TTM)
$171.4M
Shares Outstanding
148.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.82
EPS
$-0.46
Book Value
$-0.05
P/E Ratio
-4.5x
Price/Sales (TTM)
1.8
Price/Cash Flow (TTM)
---
Operating Margin
-29.47%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.